[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,721,063
  • Shares Outstanding, K 29,680
  • Annual Sales, $ 55,230 K
  • Annual Income, $ -164,080 K
  • EBIT $ -140 M
  • EBITDA $ -139 M
  • 60-Month Beta 1.16
  • Price/Sales 49.04
  • Price/Cash Flow N/A
  • Price/Book 20.70

Options Overview Details

View History
  • Implied Volatility 63.01% (+0.84%)
  • Historical Volatility 69.68%
  • IV Percentile 2%
  • IV Rank 0.67%
  • IV High 558.45% on 06/05/25
  • IV Low 59.64% on 04/22/26
  • Expected Move (DTE 20) 7.48 (8.16%)
  • Put/Call Vol Ratio 2.13
  • Today's Volume 1,161
  • Volume Avg (30-Day) 3,232
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 42,999
  • Open Int (30-Day) 33,230
  • Expected Range 84.20 to 99.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.74
  • Number of Estimates 7
  • High Estimate $-1.22
  • Low Estimate $-2.88
  • Prior Year $-3.30
  • Growth Rate Est. (year over year) +47.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
64.10 +43.03%
on 03/30/26
109.00 -15.89%
on 04/20/26
+18.72 (+25.66%)
since 03/24/26
3-Month
33.40 +174.49%
on 01/30/26
109.00 -15.89%
on 04/20/26
+54.57 (+147.05%)
since 01/23/26
52-Week
7.99 +1,047.43%
on 06/16/25
109.00 -15.89%
on 04/20/26
+80.61 (+727.85%)
since 04/24/25

Most Recent Stories

More News
Nektar Therapeutics Class Action Reminder – Robbins LLP Encourages NKTR Investors to Contact the Firm for Information About Their Rights

Robbins LLP  reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26,...

NKTR : 91.68 (+0.46%)
Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN FRANCISCO , April 23, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced the...

NKTR : 91.68 (+0.46%)
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , April 23, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR ...

NKTR : 91.68 (+0.46%)
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Known Trial Defects: SueWallSt

The Red Flags: What Insiders Allegedly Knew Before Shareholders Did

NKTR : 91.68 (+0.46%)
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Enrollment Violations: Levi & Korsinsky

Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRA

NKTR : 91.68 (+0.46%)
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit

NEW YORK , April 22, 2026 /PRNewswire/ --

NKTR : 91.68 (+0.46%)
Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering

SAN FRANCISCO , April 21, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy,...

NKTR : 91.68 (+0.46%)
NKTR INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options

NKTR : 91.68 (+0.46%)
NKTR Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in Nektar Therapeutics Securities Class Action Lawsuit -- The Gross Law Firm

NEW YORK , April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR) .

NKTR : 91.68 (+0.46%)
Nektar Therapeutics Announces Proposed Public Offering

SAN FRANCISCO , April 20, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy,...

NKTR : 91.68 (+0.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration...

See More

Key Turning Points

3rd Resistance Point 96.60
2nd Resistance Point 94.42
1st Resistance Point 93.05
Last Price 91.68
1st Support Level 89.50
2nd Support Level 87.32
3rd Support Level 85.95

See More

52-Week High 109.00
Last Price 91.68
Fibonacci 61.8% 70.41
Fibonacci 50% 58.49
Fibonacci 38.2% 46.58
52-Week Low 7.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.